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Introduction {#sec1}
============

Diseases are conventionally studied in the context of changes and responses that occur in only one or a few selected organs. For example, in studying heart diseases, the heart is the main focus point. In some cases, a few other organs (e.g., kidney, lung, brain) are included in the studies, as they are known to interact with the heart via circulating hormones and other systemic factors ([@bib32]). In investigating kidney diseases, multiple organs (e.g., bone, heart, brain, liver) are often studied on the basis of the inter-organ communication ([@bib19], [@bib20], [@bib25], [@bib56]). Tumorigenesis in a specific organ imposes critical impacts on metabolic organs, eventually causing the whole-body-level condition known as cachexia ([@bib10]). Even in this case, only a few selected organs are the subjects of the studies. Currently, we know very little about exactly to what extent diverse organs in the body are influenced in a specific disease condition.

In an effort to understand the whole-body level biology of the human and non-human model organisms, the multi-organ omics databases have been established and made available to the public. Especially, the Genotype-Tissue Expression (GTEx) ([@bib16]) and The Human Protein Atlas ([@bib54]) publish comprehensive transcriptome and transcriptome/proteome datasets of multiple organs of healthy human subjects, respectively. Most recently, an international research project referred to as Human Cell Atlas ([@bib45]) has been initiated and is aiming to have the complete whole-body map of the human at the individual cell level. A similar approach has already generated transcriptome datasets of approximately 6,000 individual cells in Drosophila ([@bib23]), a commonly used model organism in biology and medicine. Recently, we reported comprehensive whole-body transcriptome datasets of normal and several mutant zebrafish ([@bib51]), a vertebrate model frequently used for the study of biology and medicine. Although such comprehensive multi-organ datasets of healthy subjects and developmental models are being generated, comparably comprehensive multi-organ and multi-disease datasets remain limited. The Stockholm-Tartu Atherosclerosis Reverse Network Engineering Task (STARNET) has provided transcriptome datasets of several organs derived from human subjects with coronary artery diseases (CADs) ([@bib12]). However, diverse organs are yet to be represented. Furthermore, the comparable datasets for other types of diseases are not available, thus disease-to-disease comparisons remain a challenge.

Hence, what is missing is the dataset representing the body-wide diverse organs and multiple diseases. The availability of such datasets allows for the evaluations of molecular changes that occur in diverse organs in each disease model. Such datasets also make it possible to perform direct organ-to-organ comparisons among various disease models and also inter-organ comparisons within the specific model. Such analyses can be effectively used to deduce the body-wide inter-organ communication network. Furthermore, their utility could extend to the identification of disease-specific and/or organ-specific molecular signatures that could serve as biomarkers for diseases and/or molecular targets for therapeutics. Moreover, such body-wide multi-disease model datasets could be used to make organ-to-organ comparisons with human datasets to characterize similarities and dissimilarities between the mouse and human transcriptome landscapes.

In this report, we provide such datasets. We describe comprehensive transcriptome datasets of 13--23 organs from diverse disease models: myocardial infarction, diabetes, kidney diseases, brain tumor, and pre-mature aging. The data are generated from one to three stages representing early to late phases of the progression of each disease condition. For kidney diseases, we provide datasets from multiple different models, each representing overlapping but distinct risk factors for the disease. The analyses of such datasets reveal organ-to-organ similarities and dissimilarities among different disease models. They also show common and distinct features of the transcriptome landscape among distinct organs within each model. These analyses identified the skin as one of the unexpected organs that appears to sense disease-associated pathophysiological condition(s). Experimental validations found 25 genes in the skin that are differentially expressed in the kidney-disease models. We also show that their expression is differentially modulated by a bone-derived systemic factor, FGF23, suggesting a bone-skin interaction in kidney disease or related conditions. More global body-wide network analyses across multiple organs in each model identify candidates for inter-organ cross talk underlying disease-associated pathophysiological changes. The utility of our mouse model datasets is also illustrated by showing the organ-to-organ differences in the degree of similarity in the genome-wide gene expression patterns between human and each mouse model. The comparison of the mouse datasets to an orthologous human disease dataset provides an insight into the degree of the relatedness of the mouse model to human disease. We discuss the utility of such rich body-wide datasets across multiple disease models for the study of disease and also the relevance of the findings to human biology and clinical applications.

Results {#sec2}
=======

Mouse Models of Human Diseases {#sec2.1}
------------------------------

Comprehensive transcriptome data were generated from mouse models of diverse human diseases and disease-related conditions ([Figure 1](#fig1){ref-type="fig"}). We chose seven relatively well-established and widely used mouse models and generated transcriptome datasets from one to three pathophysiological stages for each model ([Figure 1](#fig1){ref-type="fig"}). Models for myocardial infarction (MI) ([@bib36]) ([Figure 1](#fig1){ref-type="fig"}A), streptozotocin (STZ)-induced diabetes ([@bib15], [@bib42]) ([Figure 1](#fig1){ref-type="fig"}B), kidney diseases and related conditions including chronic kidney disease (CKD), chronic kidney disease mineral and bone disorder (CKD-MBD) ([@bib19], [@bib22], [@bib26], [@bib27], [@bib28], [@bib25], [@bib34], [@bib49], [@bib52], [@bib59]) ([Figure 1](#fig1){ref-type="fig"}C), cancer ([@bib24]) ([Figure 1](#fig1){ref-type="fig"}D), pre-mature aging ([@bib6]) ([Figure 1](#fig1){ref-type="fig"}E), and kidney injury induced by cisplatin ([@bib33]) ([Figure 1](#fig1){ref-type="fig"}F) were generated (see [Transparent Methods](#mmc1){ref-type="supplementary-material"}) and validated ([Figures S1--S5](#mmc1){ref-type="supplementary-material"}, [Table S1. Raw Data of Ejection Fraction, Related to Figure 1](#mmc2){ref-type="supplementary-material"}, [Table S2. Raw Data of Blood Glucose in STZ Model, Related to Figure 1](#mmc3){ref-type="supplementary-material"}, [Table S3. Raw Data of Inorganic Phosphorus in Plasma for CKD Models and HPi4w Model, Related to Figure 1](#mmc4){ref-type="supplementary-material"}, [Table S4. Raw Data of Creatinine in Plasma for CKD Models and HPi4w Model, Related to Figure 1](#mmc5){ref-type="supplementary-material"}, [Table S5. Raw Data of ELISA for FGF23 in Plasma for CKD Models and HPi4w Model, Related to Figure 1](#mmc6){ref-type="supplementary-material"}, [Table S6. Raw Data of qRT-PCR for GBM Model, Related to Figure 1](#mmc7){ref-type="supplementary-material"}, [Table S7. Raw Data of Step-through Test for SAMP8 Mouse, Related to Figure 1](#mmc8){ref-type="supplementary-material"}, [Table S8. Raw Data of Inorganic Phosphorus in Plasma for Phosphorus Overload Models, Related to Figure 1](#mmc9){ref-type="supplementary-material"}, [Table S9. Raw Data of ELISA for FGF23 in Plasma for Phosphorus Overload Models in WT and FGF23-Deficient Mice, Related to Figure 1](#mmc10){ref-type="supplementary-material"}).Figure 1Mouse ModelsEach model and the organs analyzed are described (See [Transparent Methods](#mmc1){ref-type="supplementary-material"} for the details).

Comparative Analyses of the Mouse RNA-Sequence Datasets {#sec2.2}
-------------------------------------------------------

From each model and control mice (WT and WT + Saline) (see [Transparent Methods](#mmc1){ref-type="supplementary-material"}), 13--23 organs were harvested and processed for RNA sequence (RNAseq) analyses (see [Transparent Methods](#mmc1){ref-type="supplementary-material"}). The overall quality of the sequence data was demonstrated by the virtually identical gene expression patterns between the control datasets (WT and WT + Saline) and the publicly available wild-type (WT) mouse datasets ([@bib38]) ([Figure S6](#mmc1){ref-type="supplementary-material"}). A subtle difference could be attributed to strain, age, sex, or housing-condition differences (see [Transparent Methods](#mmc1){ref-type="supplementary-material"}). The validity of the datasets was further confirmed by the regulated expressions of the known disease marker genes ([@bib4], [@bib8], [@bib18], [@bib21], [@bib37], [@bib39], [@bib43], [@bib44], [@bib46], [@bib50], [@bib53], [@bib58]) ([Figure 2](#fig2){ref-type="fig"}). To evaluate how broadly the gene expressions are altered across various organs, we compared both model and sham control with WT control datasets independently using DESeq2 analysis. For convenience, we used 2-fold change as differentially expressed genes (i.e., \|log~2~(fold-change)\| \> 1) with p \< 0.0001 (Wald test and adjusted by Benjamini-Hochberg method). The number of such differentially expressed genes specifically for one organ in each model, but not in the corresponding sham control, was counted. In addition, the number of the differentially expressed genes in multiple organs for all combinations of the organs in each model, but not in the corresponding sham control, was also counted. The results of such organ-to-organ comparisons for each model are shown in [Figure 3](#fig3){ref-type="fig"}. It is important to note that the organs analyzed for each model overlap but are not identical; thus the model-to-model comparison should not be performed using these graphs. Hence, for the model-to-model comparison for each organ, the number of differentially expressed genes in each organ isolated from each model was analyzed ([Figure 4](#fig4){ref-type="fig"}). The number of differentially expressed genes specifically in one model or sham control, but not in the other models or sham controls, and also in multiple combinations of the models/sham controls, but not in other combinations was counted. The results of such model-to-model comparisons for each organ are shown in [Figure 4](#fig4){ref-type="fig"}.Figure 2Differential Expression of Known Regulated Genes in Each ModelFPKM (fragments per kilobase million) of each gene in each organ sample is plotted as bar graph. All organs (left) and the select organs known for the regulated expression of the genes (right) are shown. The model names are according to those shown in [Figure 1](#fig1){ref-type="fig"}. The gene name is indicated on the left of each graph. The organs for which the sequence datasets are not available for each model are indicated as • on the x axis of each graph.Figure 3Organ-to-Organ Comparisons of the Differentially Expressed Genes for Each ModelThe color or the colors (the vertical alignment) at the bottom indicate the organ or the combination of the organs, respectively. The differentially expressed genes in each organ/organ combination of each model were identified by comparison with the corresponding dataset of WT. The number (in log~2~) of the differentially expressed genes in each organ/organ combination of each disease model, but not in that of the corresponding sham control, was counted and is shown as bar graph for each model. The number (in log~2~) of the differentially expressed genes in each organ/organ combination of the cisplatin model, as compared with the corresponding dataset of WT, was counted and is shown as bar graph. It is important to note that the organs analyzed for each model overlap but are not identical (see [Figure 1](#fig1){ref-type="fig"}). The organs that are not represented in each model are indicated by blue-color x axis line. Thus the comparison is valid only among the organs that are represented in each organ. The corresponding organ-to-organ comparisons of the GO terms are shown in [Figure S7](#mmc1){ref-type="supplementary-material"}.Figure 4Model-to-Model Comparisons of the Gene Expression for Each OrganThe color or the colors (the vertical alignment) at the bottom indicate the model or the model combinations, respectively. The number (in log~2~) of the differentially expressed genes (as compared with the corresponding WT dataset) in each model/model combination of each organ was counted and is shown as bar graph for each model. Only organs that are common to all models are analyzed and shown. The model-to-model comparisons of the GO terms are shown in [Figure S8](#mmc1){ref-type="supplementary-material"}.

As expected, the organ(s) that is(are) conventionally known to show pathophysiological responses in each model show a large number of differentially expressed genes. In the MI models, the clusters of taller bars in the heart and the combinations including the heart are obvious ([Figure 3](#fig3){ref-type="fig"}). A closer examination found 1,302, 1,891, and 1,178 differentially expressed genes in the heart or the organ combinations, including the heart of E-MI, M-MI, and L-MI, respectively, but not in the corresponding sham-control models ([Tables S10](#mmc11){ref-type="supplementary-material"} and [S11](#mmc12){ref-type="supplementary-material"}). Furthermore, according to the ranking in the number of differentially expressed genes in the heart, the M-MI model is the first with 629 genes ([Figure 4](#fig4){ref-type="fig"} and [Table S12](#mmc13){ref-type="supplementary-material"}). The second is E−/M-MI models with 261 genes (i.e., 261 genes are differentially expressed in both E− and M-MI models) ([Figure 4](#fig4){ref-type="fig"} and [Table S12](#mmc13){ref-type="supplementary-material"}). The third (253 genes), fourth (133 genes), fifth (105 genes), and sixth (102 genes) were E-MI model, M-/L-MI models, E−/M-/L-MI models, and L-MI model, respectively ([Figure 4](#fig4){ref-type="fig"} and [Table S12](#mmc13){ref-type="supplementary-material"}). The genes that are also regulated in the corresponding sham controls were excluded in this ranking ([Figure 4](#fig4){ref-type="fig"} and [Table S12](#mmc13){ref-type="supplementary-material"}). In the kidney disease models, we found 499, 631, and 1,124 differentially expressed genes in the kidney or the organ combinations, including the kidney of E-CKD, M-CKD, and L-CKD, respectively, but not in the corresponding sham-control models ([Figure 3](#fig3){ref-type="fig"}, [Tables S10](#mmc11){ref-type="supplementary-material"} and [S11](#mmc12){ref-type="supplementary-material"}). In the cisplatin-treated model, the kidney shows 1,482 differentially expressed genes ([Figure 3](#fig3){ref-type="fig"}, [Tables S10](#mmc11){ref-type="supplementary-material"} and [S11](#mmc12){ref-type="supplementary-material"}).

However, the overall landscape of the organ-to-organ and the model-to-model comparisons was more complex than anticipated. It appears that the differential gene expression patterns extend to more diverse organ types than conventionally assumed ([Figure 3](#fig3){ref-type="fig"}). Although, in each model, the number of differentially expressed genes varies from organ to organ and also depends on the organ combinations, the differentially expressed genes are broadly distributed across organs and organ combinations ([Figure 3](#fig3){ref-type="fig"}). The organ-to-organ comparisons of Gene Ontology (GO) terms of the differentially expressed genes also show the overlapping and distinct distribution pattern for each organ ([Figure S7](#mmc1){ref-type="supplementary-material"} and [Table S13](#mmc14){ref-type="supplementary-material"}). In the model-to-model comparisons ([Figure 4](#fig4){ref-type="fig"}), the differentially expressed genes in each organ can be detected both in a specific model and also are shared among multiple organs, as indicated by the broadly distributed patterns of the bars in each graph ([Figure 4](#fig4){ref-type="fig"}). A closer examination also identifies the lack of differentially expressed genes in a certain model(s) and/or a model combination(s), as indicated by the lack of the bars ([Figure 4](#fig4){ref-type="fig"}). A common distribution pattern can also be found among the organs, suggesting the possibility that some organs respond more robustly than the others ([Figure 4](#fig4){ref-type="fig"}). The model-to-model comparisons of GO terms of the differentially expressed genes in each organ also show both the model/model-combination-specific GO terms and those shared by multiple models/model combinations ([Figure S8](#mmc1){ref-type="supplementary-material"} and [Table S13](#mmc14){ref-type="supplementary-material"}).

The Skin as a Disease Sensor? {#sec2.3}
-----------------------------

We show that differential gene expression can be found broadly across diverse organs ([Figure 3](#fig3){ref-type="fig"}). In particular, the skin is one of the most robustly affected organs ([Figure 3](#fig3){ref-type="fig"}, [Tables S10](#mmc11){ref-type="supplementary-material"} and [S11](#mmc12){ref-type="supplementary-material"}). In each model, but not in the corresponding sham control, a large number of genes are differentially expressed in the skin: 337 (E-MI), 378 (M-MI), 248 (L-MI), 477 (E-CKD), 294 (M-CKD), 707 (L-CKD), 361 (E-STZ), 349 (M-STZ), 974 (E-SAMP8), 3,731 (M-SAMP8), 526 (L-SAMP8), 381 (E-GBM), 267 (M-GBM), 79 (HPi4w), 2,011 (Cisplatin) genes ([Figure 3](#fig3){ref-type="fig"}, [Tables S10](#mmc11){ref-type="supplementary-material"} and [S11](#mmc12){ref-type="supplementary-material"}). The model-specific differentially expressed skin genes were also found: 8 (E-MI), 10 (M-MI), 2 (L-MI), 13 (E-CKD), 6 (M-CKD), 28 (L-CKD), 21 (E-STZ), 38 (M-STZ), 110 (E-SAMP8), 2,160 (M-SAMP8), 33 (L-SAMP8), 5 (E-GBM), 25 (M-GBM), 6 (HPi4w), 536 (Cisplatin) genes ([Figure 4](#fig4){ref-type="fig"} and [Table S12](#mmc13){ref-type="supplementary-material"}).

Next, we applied Weighted Gene Co-expression Network Analysis (WGCNA) to identify signature gene expression network activities of the skin that distinguish one pathophysiological condition from the other ([Figure 5](#fig5){ref-type="fig"} and see [Transparent Methods](#mmc1){ref-type="supplementary-material"}). For each model, we found a set of modules consisting of unique GO terms that show relatively stronger positive or negative correlation with a specific pathophysiological condition (e.g., E., M., L.) than with the others ([Figure 5](#fig5){ref-type="fig"} and [Table S14](#mmc15){ref-type="supplementary-material"}).Figure 5Signature Gene Expression Network Activities of the SkinThe result of WGCNA using the skin datasets of the MI models (A), the STZ-induced diabetes models (B), the CKD models (C), the CKD and phosphorus-overload models (D), the CKD, the phosphorus-overload, and the cisplatin-induced kidney injury models (E), the tumor models (F), and the pre-mature aging models (G) are shown (see [Transparent Methods](#mmc1){ref-type="supplementary-material"}). The top two GO terms are shown for each module on the left. The correlation coefficient and the p value (Student\'s asymptotic t test) of each module and the complete list of GO terms with their p values (Fisher\'s exact test) are shown in [Table S14](#mmc15){ref-type="supplementary-material"}.

The WGCNA of the skin of the MI models identified the modules that show relatively strong negative correlations with E.MI or L.MI. The former module consists of GO terms such as "regulation of viral life cycle" and "viral budding" ([Figure 5](#fig5){ref-type="fig"}A and [Table S14](#mmc15){ref-type="supplementary-material"}), suggesting that the downregulation of these processes signifies the skin condition of E.MI. The latter module consists of GO terms such as "modulation by virus of host morphology or physiology," "circulatory system," and "vascular development" ([Figure 5](#fig5){ref-type="fig"}A and [Table S14](#mmc15){ref-type="supplementary-material"}), suggesting that the suppression of these processes may represent the skin condition of L.MI.

The analysis of the skin of the STZ-induced diabetes model identified one module that shows a strong negative correlation with E.STZ and the other module that exhibits a strong positive correlation with M.STZ ([Figure 5](#fig5){ref-type="fig"}B and [Table S14](#mmc15){ref-type="supplementary-material"}). The former consists of GO terms such as "positive regulation of cellular process" and "positive regulation of signal transduction" ([Figure 5](#fig5){ref-type="fig"}B and [Table S14](#mmc15){ref-type="supplementary-material"}), suggesting that the downregulation of these processes represents the skin condition of E.STZ. The latter module consists of GO terms such as "positive regulation of type I interferon-mediated signaling pathway" and "cellular response to type I interferon" ([Figure 5](#fig5){ref-type="fig"}B and [Table S14](#mmc15){ref-type="supplementary-material"}), suggesting that the enhanced activities of such processes may signify the skin condition of M.STZ.

The WGCNA of the skin of the CKD models found the modules that distinguish L.CKD from the others, and they consist of unique GO terms such as "intracellular protein transport," "response to wounding," "single-organism cellular processes," and "muscle structure development" ([Figure 5](#fig5){ref-type="fig"}C and [Table S14](#mmc15){ref-type="supplementary-material"}), suggesting that the upregulation of such processes in the skin represents L.CKD-specific pathophysiological conditions.

The inclusion of the phosphorus-overload models to the CKD models in the analysis resulted in the modular pattern where no modules show outstandingly strong correlations with any models ([Figure 5](#fig5){ref-type="fig"}D). This result suggests that the skin conditions of these models are relatively similar.

A comparison of the cisplatin model with the CKD and phosphorus-overload models identified positively and negatively correlating modules with the cisplatin model ([Figure 5](#fig5){ref-type="fig"}E and [Table S14](#mmc15){ref-type="supplementary-material"}). The positively correlating modules consist of GO terms such as "metabolic process" and "catabolic process" ([Figure 5](#fig5){ref-type="fig"}E and [Table S14](#mmc15){ref-type="supplementary-material"}). The negatively correlating module consists of GO terms such as "extracellular matrix organization," "collagen fibril organization," and "lipid metabolic process" ([Figure 5](#fig5){ref-type="fig"}E and [Table S14](#mmc15){ref-type="supplementary-material"}), suggesting that the downregulation of such processes in the skin represents the cisplatin-model-specific condition.

The analysis of the tumor model identified a module that shows strong correlation with M.GBM ([Figure 5](#fig5){ref-type="fig"}F). The module consists of GO terms such as "response to interferon-beta" and "response to cytokine" ([Figure 5](#fig5){ref-type="fig"}F and [Table S14](#mmc15){ref-type="supplementary-material"}), suggesting that the upregulation of such processes signifies the skin condition of M.GBM but not of E.GBM.

The WGCNA of the pre-mature aging models identified several modules that distinguish one pathophysiological condition from the other ([Figure 5](#fig5){ref-type="fig"}G). The modules consisting of GO terms such as "cellular metabolic process" and "organic substance metabolic process". appear to distinguish M.SAMP8 from the others ([Figure 5](#fig5){ref-type="fig"}G and [Table S14](#mmc15){ref-type="supplementary-material"}). The module consisting of GO terms such as "regulation of protein metabolic process," "organic substance metabolic process," and "leukocyte migration involved in inflammatory response" shows a strong negative correlation specifically with L.SAMP8 ([Figure 5](#fig5){ref-type="fig"}G and [Table S14](#mmc15){ref-type="supplementary-material"}), suggesting that the downregulation of such processes distinguish the L.SAMP8 skin condition from the others.

These and other modules showing relatively stronger correlations and lower p values could be signature activities of the gene expression network in the skin for that specific pathophysiological condition in the model. These results are also in support of the idea that the skin is a disease-sensor organ.

Although a variety of skin pathophysiological conditions are implicated for a variety of non-skin diseases ([@bib5], [@bib11], [@bib13], [@bib14], [@bib55]), the evidence remains relatively weak. Furthermore, the molecular mechanism underlying such skin pathologies and/or conditions remains elusive. Our results with the mouse models suggest the existence of unique signature activities of gene expression network in the skin that represent a specific pathophysiological condition of each disease model, providing molecular and system level evidence for the skin as a disease-sensor organ. In fact, such findings are not limited to the mouse models. We performed RNAseq analyses of skin biopsies from eight patients with breast cancer and three patients with lung cancer ([Figure 6](#fig6){ref-type="fig"}). These analyses demonstrate that gene expression changes occur in the skin in non-skin diseases such as breast and lung cancer in human ([Figure 6](#fig6){ref-type="fig"}). Furthermore, there exist gene expression changes that are conserved and specific to each cancer type and that are common for both ([Figure 6](#fig6){ref-type="fig"}).Figure 6Comparison of the Gene Expression Patterns in the Skin Derived from Patients with CancerThe number of upregulated (Up-genes) (A) and downregulated (Down-genes) (B) genes is indicated in the Venn diagram. The differential expression levels of the upregulated (C) and downregulated (D) genes are shown in the heatmap. Those that are non-significant as defined by p ≥ 0.0001 are indicated by ■.

To further investigate the regulatory mechanisms underlying the gene expression changes in the skin in non-skin diseases, we studied the differential gene expression changes in the skin in our mouse models ([Figures 3](#fig3){ref-type="fig"}, [4](#fig4){ref-type="fig"}, and [5](#fig5){ref-type="fig"}). Several pathophysiological skin conditions are observed in renal diseases in human. However, very little is known about the molecular signatures of such skin conditions. Furthermore, the molecular mechanism underlying the emergence of such skin conditions in renal diseases remains enigmatic. Hence, we characterized the gene expression changes found in the models of kidney diseases.

We selected 25 differentially expressed genes in the skin of E-CKD, M-CKD, and L-CKD models, and unilateral nephrectomy followed by phosphate overload was imposed on the mice. The qRT-PCR analysis validated the varying degrees of up- and down-regulation in one or more of the CKD models: 14 were upregulated ([Figure 7](#fig7){ref-type="fig"}A and [Table S15](#mmc16){ref-type="supplementary-material"}) and 11 were downregulated ([Figure 7](#fig7){ref-type="fig"}B and [Table S15](#mmc16){ref-type="supplementary-material"}).Figure 7Differentially Expressed Skin Genes in the CKD ModelsThe qRT-PCR results for each upregulated (A) and downregulated (B) gene are shown. n = 9 (E.Sham), n = 9 (E.CKD), n = 9 (M.Sham), n = 9 (M.CKD), n = 9 (L.Sham), n = 8 (L.CKD).\*p \< 0.05, \*\*p \< 0.01, and \*\*\*p \< 0.001, Mann Whitney U-test. The mean is indicated by a horizontal line.

The Bone-Skin Cross talk and FGF23 {#sec2.4}
----------------------------------

Next, we designed an experiment to gain a mechanistic insight into the differential expression of the genes. We hypothesized that a systemic factor derived from a non-skin organ(s) mediates such differential gene expression in the skin of CKD models. FGF23 could be a candidate. FGF23 is a bone-derived hormone that regulates phosphate homeostasis and is implicated in kidney diseases ([@bib2], [@bib3], [@bib17], [@bib19], [@bib26], [@bib27], [@bib28], [@bib25], [@bib35], [@bib40], [@bib41], [@bib48], [@bib49], [@bib57], [@bib60]). In fact, we show that the level of the circulating FGF23 is significantly increased in the CKD models ([Figure S3](#mmc1){ref-type="supplementary-material"}C). Therefore, we tested this hypothesis by characterizing FGF23-deficient mice ([Figure S9](#mmc1){ref-type="supplementary-material"}A). FGF23-deficient mice were generated by the CRISPR/Cas9 method ([Figure S9](#mmc1){ref-type="supplementary-material"}A and see [Transparent Methods](#mmc1){ref-type="supplementary-material"}). As FGF23-deficient mice progressively weaken postnatally ([@bib48], [@bib49]), we developed another phosphate-overload model using mice 3--4 weeks old. WT mice 3 weeks old (they are weaned at 3 weeks old) were fed *ad libitum* with a diet containing low (0.35%), normal (0.54%), or high (2%) levels of inorganic phosphate for 1 week (see [Transparent Methods](#mmc1){ref-type="supplementary-material"} for the details). In this model, both the plasma phosphate ([Figure S9](#mmc1){ref-type="supplementary-material"}B) and FGF23 ([Figure S9](#mmc1){ref-type="supplementary-material"}C) levels increase in the WT mice. FGF23-deficient (FGF23KO) mice at 3 weeks and 1 day old (they are weaned at 3 weeks old) were also fed with the diet containing normal (0.54%) or high (2%) levels of inorganic phosphate for 1 week (see [Transparent Methods](#mmc1){ref-type="supplementary-material"} for the details). In these FGF23KO mice, the plasma FGF23 is barely detectable, confirming the null mutation of the gene ([Figure S9](#mmc1){ref-type="supplementary-material"}C). Furthermore, the plasma phosphate level increases even without the phosphate overload ([Figure S9](#mmc1){ref-type="supplementary-material"}B), corroborating the known function of FGF23 as a hormone facilitating phosphate excretion ([@bib2], [@bib26], [@bib25], [@bib49]). The FGF23KO mice show the increased plasma phosphate level upon the phosphate overload (FGF23KO1WHP in [Figure S9](#mmc1){ref-type="supplementary-material"}B), confirming that they indeed take in the high-phosphate diet. The expressions of the 25 skin genes were analyzed by qRT-PCR in this model ([Figure 8](#fig8){ref-type="fig"}). The expression of each gene in the younger mice loaded with a high-phosphate diet for 1 week (WT1WHP) was compared with that with a low-phosphate diet (WT1WLP). The result showed 5 upregulated (*Hamp2*: ca. x3.6, *Cxcl13*: ca. x2.3, *Ptp4a3*: ca. x1.3, *Serpinb6e*: ca. x2.0, *Il22ra2*: ca. x1.6) ([Figure 8](#fig8){ref-type="fig"}A and [Table S16](#mmc17){ref-type="supplementary-material"}) and 10 downregulated genes (*Col15a1*: ca. x0.7, *Aldh1l2*: ca. x0.3, *Clec11a*: ca. x0.3, *Serpinb6d*: ca. x0.3, *Defb8*: ca. x0.01, *Col3a1*: ca. x0.5, *C1qtnf6*: ca. x0.4, *Sparc*: ca. x0.5, *Col1a1*: ca. x0.4, *Col5a1*: ca. x0.6) ([Figures 8](#fig8){ref-type="fig"}B, 8D, and [Table S16](#mmc17){ref-type="supplementary-material"}). The expression of Nrap also appears to be downregulated (ca. x0.8), but the p value was only 0.01074 ([Figure 8](#fig8){ref-type="fig"}C and [Table S16](#mmc17){ref-type="supplementary-material"}). The expressions of nine genes (*Actn3*, *Asb11*, *Klhl38*, *Atp2a1*, *Myot*, *Pde4dip*, *Rbfox1*, *Lrrc2*, *Col11a1*) show no significant changes ([Figure 8](#fig8){ref-type="fig"}C and [Table S16](#mmc17){ref-type="supplementary-material"}).Figure 8Differentially Expressed Skin Genes in the Phosphorus-Overload Models in Wild Type (WT) and FGF23-Deficient (FGF23KO) MiceThe qRT-PCR results for genes that are upregulated (A), downregulated (B), unaffected (C), and downregulated but relatively less affected by the FGF23KO (D) upon phosphate overload are shown. The phosphate overload was initiated at 3 weeks old for all WT and indicated as WT(3W). For FGF23KO, the phosphate overload was initiated at 3 weeks plus 1 day and indicated as FGF23KO (3W+1d). For all graphs in (A) and the WT(3W)1WHP vs. FGF23KO(3W+1d)1WND and the WT(3W)1WHP vs. FGF23KO(3W+1d)1WHP comparisons for *Defb8* in (B), it may be difficult to see the upregulation (A) or downregulation even with the statistical significance. This results from accommodating widely distributed dots along the y axis in the same graph. The statistically significant and robust gene expression changes can be confirmed by examining the raw data and statistical analyses shown in [Table S16](#mmc17){ref-type="supplementary-material"}. LP, low-phosphorus diet; ND, normal diet; HP, high-phosphorus diet. n = 13--14 (WT1WLP), n = 12 (WT1WND), n = 14 (WT1WHP), n = 12 (FGF23KO1WND), n = 7 (FGF23KO1WHP).\*p \< 0.05, \*\*p \< 0.01, and \*\*\*p \< 0.001, Mann Whitney U-test. The mean is indicated by a horizontal line.

Next, the effect of FGF23 deficiency was examined using the FGF23-deficient mice ([Figure 8](#fig8){ref-type="fig"}). The comparisons were made as follows: WT with the normal diet (WT1WND) vs. FGF23KO with the normal diet (FGF23KO1WND), WT with the high-phosphate diet (WT1WHP) vs. FGF23KO with the high-phosphate diet (FGF23KO1WHP), and WT with the high-phosphate diet (WT1WHP) vs. FGF23KO with the normal-phosphate diet (FGF23KO1WND). The plasma phosphate level in the WT mice fed with the high phosphate shows an increase in the blood phosphate level that is comparable with that of the FGF23KO mice fed with the normal diet ([Figure S9](#mmc1){ref-type="supplementary-material"}B). Therefore, the comparison between WT1WHP and FGF23KO1WND was made to account for the influence of the high phosphate level in the blood. These analyses show that the upregulated expression of all five genes (*Hamp2*, *Cxcl13*, *Ptp4a3*, *Serpinb6e*, *Il22ra2*) is further upregulated in the FGF23KO mice ([Figure 8](#fig8){ref-type="fig"}A and [Table S16](#mmc17){ref-type="supplementary-material"}). The downregulated expression of five genes (*Col15a1*, *Aldh1l2*, *Clec11a*, *Serpinb6d*, *Defb8*) is further downregulated in the FGF23KO mice ([Figure 8](#fig8){ref-type="fig"}B and [Table S16](#mmc17){ref-type="supplementary-material"}). Although the expression of *Actn3*, *Asb11*, *Klhl38*, *Atp2a1*, *Myot*, *Pde4dip*, *Rbfox1*, *Lrrc2*, and *Nrap* is merely unaffected by the phosphate overload (WT1WLP vs. WT1WHP), their expression is significantly upregulated by the FGF23 deficiency ([Figure 8](#fig8){ref-type="fig"}C and [Table S16](#mmc17){ref-type="supplementary-material"}). In contrast, the expression of *Col11a1*, the other gene that is unaffected by the phosphate overload, is downregulated by the FGF23 deficiency ([Figure 8](#fig8){ref-type="fig"}C and [Table S16](#mmc17){ref-type="supplementary-material"}). These results suggest that, upon phosphate overload the concurrent upregulation of FGF23 suppresses the excessive upregulation (*Hamp2*, *Cxcl13*, *Ptp4a3*, *Serpinb6e*, *Il22ra2*) ([Figure 8](#fig8){ref-type="fig"}A) and downregulation (*Col15a1*, *Aldh1l2*, *Clec11a*, *Serpinb6d*, *Defb8*) of the gene expression in the skin ([Figure 8](#fig8){ref-type="fig"}B). For *Actn3*, *Asb11*, *Klhl38*, *Atp2a1*, *Myot*, *Pde4dip*, *Rbfox1*, *Lrrc2*, *Col11a1*, and *Nrap*, the phosphate-overload-induced FGF23 upregulation suppresses and maintains the expression level even with the phosphate overload ([Figure 8](#fig8){ref-type="fig"}C), i.e., the phosphate-overload-induced FGF23 upregulation functions as a break for their otherwise upregulated (*Actn3*, *Asb11*, *Klhl38*, *Atp2a1*, *Myot*, *Pde4dip*, *Rbfox1*, *Lrrc2*, *Nrap*) or downregulated (*Col11a1*) expression ([Figure 8](#fig8){ref-type="fig"}C).

The analyses also found evidence for a pathway that is less dependent on FGF23. For *Col3a1*, *C1qtnf6*, *Sparc*, and *Col1a1*, only slight downregulation is detected in the WT1WHP vs. FGF23KO1WHP comparison ([Figure 8](#fig8){ref-type="fig"}D), but not in the WT1WHP vs. FGF23KO1WND one ([Figure 8](#fig8){ref-type="fig"}D), despite the comparable increase in the blood phosphate level ([Figure S9](#mmc1){ref-type="supplementary-material"}B). For *Col5a1*, neither WT1WND vs. FGF23KO1WND nor WT1WHP vs. FGF23KO1WHP comparison found statistically significant differences in the *Col5a1* expression ([Figure 8](#fig8){ref-type="fig"}D and [Table S16](#mmc17){ref-type="supplementary-material"}). The WT1WHP vs. FGF23KO1WND comparison shows only marginal, if any, upregulation (ca. x1.7), with the p value of 0.0132 ([Figure 8](#fig8){ref-type="fig"}D and [Table S16](#mmc17){ref-type="supplementary-material"}). These results suggest that the increased FGF23 level upon the phosphate overload influences very little, if any, of the phosphate-overload-mediated downregulation of these five skin genes.

The signaling by FGF23 is mediated by a cell surface receptor complex consisting of α-Klotho and FGFRs ([@bib19], [@bib22], [@bib47]). To gain further insight into this bone-skin cross talk mediated by FGF23, we examined the body-wide expression patterns of *αKlotho* and *Fgfrs* ([Figure 9](#fig9){ref-type="fig"}). The expression of *αKlotho* is most abundant in the kidney as previously described ([@bib29]), but very little, if any, expression was detected in the skin ([Figure 9](#fig9){ref-type="fig"}). The transcripts for the co-receptors, *Fgfrs*, are more ubiquitously expressed ([Figure 9](#fig9){ref-type="fig"}). As αKlotho is the requisite receptor component for the FGF23 signaling ([@bib7], [@bib19], [@bib22], [@bib30], [@bib47]), it is unlikely that FGF23 acts directly on the skin. Instead, the FGF23 effects are mediated by yet another factor(s) that is(are) regulated by FGF23.Figure 9Expression Patterns of *α-Klotho, Fgfr1, Fgfr2, Fgfr3*, and *Fgfr4* across the OrgansThe FPKM for each gene in each sample is shown as bar graph. The organ names are indicated at the bottom. Shown are for all CKD models and the sham controls.

Putative Inter-Organ Cross talk Network {#sec2.5}
---------------------------------------

The characterization of the skin gene expressions in the disease models led us to identify the bone-skin cross talk mediated by the bone-derived hormone FGF23 and its regulation by phosphate homeostasis ([Figures 7](#fig7){ref-type="fig"} and [8](#fig8){ref-type="fig"}). Hence, we next took advantage of the rich multi-organ datasets across multiple disease models to identify more signature activities of inter-organ cross talk for the disease models. WGCNA was applied to the datasets for each disease model ([Figures 10](#fig10){ref-type="fig"}, [11](#fig11){ref-type="fig"}, [12](#fig12){ref-type="fig"}, [13](#fig13){ref-type="fig"}, [14](#fig14){ref-type="fig"}, [15](#fig15){ref-type="fig"}, and [16](#fig16){ref-type="fig"} and see [Transparent Methods](#mmc1){ref-type="supplementary-material"}). This analysis identified modules consisting of multiple organ GO term units in each model ([Figures 10](#fig10){ref-type="fig"}, [11](#fig11){ref-type="fig"}, [12](#fig12){ref-type="fig"}, [13](#fig13){ref-type="fig"}, [14](#fig14){ref-type="fig"}, [15](#fig15){ref-type="fig"}, and [16](#fig16){ref-type="fig"}). We found several modules in each disease model that exhibit a relatively stronger correlation with a specific pathophysiological condition than with the others ([Figures 10](#fig10){ref-type="fig"}, [11](#fig11){ref-type="fig"}, [12](#fig12){ref-type="fig"}, [13](#fig13){ref-type="fig"}, [14](#fig14){ref-type="fig"}, [15](#fig15){ref-type="fig"}, and [16](#fig16){ref-type="fig"}, [Table S17. All GO Terms in Each Module, Related to Figure 10](#mmc18){ref-type="supplementary-material"}, [Table S18. All GO Terms in Each Module, Related to Figure 11](#mmc19){ref-type="supplementary-material"}, [Table S19. All GO Terms in Each Module, Related to Figure 12](#mmc20){ref-type="supplementary-material"}, [Table S20. All GO Terms in Each Module, Related to Figure 13](#mmc21){ref-type="supplementary-material"}, [Table S21. All GO Terms in Each Module, Related to Figure 14](#mmc22){ref-type="supplementary-material"}, [Table S22. All GO Terms in Each Module, Related to Figure 15](#mmc23){ref-type="supplementary-material"}, [Table S23. All GO Terms in Each Module, Related to Figure 16](#mmc24){ref-type="supplementary-material"}).Figure 10Characterization of Putative Inter-Organ Cross talk in the MI ModelsModules identified by WGCNA using the datasets of the MI models are shown. The top GO term of each organ for each module is indicated by the number and is described in full in [Table S17](#mmc18){ref-type="supplementary-material"}. The organ(s) that is(are) not represented in the module is(are) indicated by ■. The correlation coefficient and the p value (Student\'s asymptotic t test) of each module and the complete list of GO terms with their p values (Fisher\'s exact test) are shown in [Table S17](#mmc18){ref-type="supplementary-material"}.Figure 11Characterization of Putative Inter-Organ Cross talk in the STZ-Induced Diabetes ModelsModules identified by WGCNA using the datasets of the STZ-induced diabetes models are shown. The correlation coefficient and the p value (Student\'s asymptotic t test) of each module and the complete list of GO terms with their p values (Fisher\'s exact test) are shown in [Table S18](#mmc19){ref-type="supplementary-material"}.Figure 12Characterization of Putative Inter-Organ Cross talk in the CKD ModelsModules identified by WGCNA using the datasets of the CKD models are shown. The organ(s) that is(are) not represented in the module is(are) indicated by ■. The correlation coefficient and the p value (Student\'s asymptotic t test) of each module and the complete list of GO terms with their p values (Fisher\'s exact test) are shown in [Table S19](#mmc20){ref-type="supplementary-material"}.Figure 13Characterization of Putative Inter-Organ Cross talk in the CKD and Phosphorus-Overload ModelsModules identified by WGCNA using the datasets of the CKD and phosphorus-overload models are shown. The organ(s) that is(are) not represented in the module is(are) indicated by ■. The correlation coefficient and the p value (Student\'s asymptotic t test) of each module and the complete list of GO terms with their p values (Fisher\'s exact test) are shown in [Table S20](#mmc21){ref-type="supplementary-material"}.Figure 14Characterization of Putative Inter-Organ Cross talk in the CKD, the Phosphorus-Overload, and the Cisplatin-Induced Kidney Injury ModelsModules identified by WGCNA using the datasets of the CKD, the phosphorus-overload, and the cisplatin-induced kidney injury models are shown. The organ(s) that is(are) not represented in the module is(are) indicated by ■. The correlation coefficient and the p value (Student\'s asymptotic t test) of each module and the complete list of GO terms with their p values (Fisher\'s exact test) are shown in [Table S21](#mmc22){ref-type="supplementary-material"}.Figure 15Characterization of Putative Inter-Organ Cross talk in the Tumor ModelsModules identified by WGCNA using the datasets of the tumor models are shown. The organ(s) that is(are) not represented in the module is(are) indicated by ■. The correlation coefficient and the p value (Student\'s asymptotic t test) of each module and the complete list of GO terms with their p values (Fisher\'s exact test) are shown in [Table S22](#mmc23){ref-type="supplementary-material"}.Figure 16Characterization of Putative Inter-Organ Cross talk in the Pre-Mature Aging ModelsModules identified by WGCNA using the datasets of the premature-aging models are shown. The organ(s) that is(are) not represented in the module is(are) indicated by ■. The correlation coefficient and the p value (Student\'s asymptotic t test) of each module and the complete list of GO terms with their p values (Fisher\'s exact test) are shown in [Table S23](#mmc24){ref-type="supplementary-material"}.

For example, in the MI model ([Figure 10](#fig10){ref-type="fig"}), the "red" module shows the strongest correlation (correlation coefficient, 0.87786; p value, 2.06 × 10^−12^) with E.MI. The top-ranked organ GO term units for each organ in this module are "bone marrow (BM) regulation of viral budding via host ESCRT complex (ID: 1084)," "brain transport (ID: 1258)," "heart cellular metabolic process (ID: 129)," "kidney small molecule metabolic process (ID: 1192)," "liver metabolic process (ID: 477)," "lung immune response (ID: 365)," "pancreas cellular amino acid metabolic process (ID: 120)," "skeletal muscle (SkMuscle) macromolecule catabolic process (ID: 445)," "spleen metabolic process (ID: 477)," "testis negative regulation of response to DNA damage stimulus (ID: 652)," "thymus cellular response to epidermal growth factor stimulus (ID: 148)," and "white adipose tissue (WAT) regulation of I-κB kinase/NF-κB signaling (ID: 999)" ([Figure 10](#fig10){ref-type="fig"} and [Table S17](#mmc18){ref-type="supplementary-material"}).

In the CKD model ([Figure 12](#fig12){ref-type="fig"}), the "paleturquoise" module shows the strongest correlation (correlation coefficient, 0.968783; p value: 2.22 × 10^−7^) with E.CKD ([Figure 12](#fig12){ref-type="fig"} and [Table S19](#mmc20){ref-type="supplementary-material"}). The top-ranked organ GO terms for each organ in this module are "adrenal gland (AdrenalG)-female gamete generation (ID: 201)," "aorta positive regulation of B cell apoptotic process (ID: 473)," "brain-intermediate filament organization (ID: 260)," "colon-formation of cytoplasmic translation initiation complex (ID: 205)," "eye chemoattraction of dopaminergic neuron axon (ID: 114)," "heart regulation of platelet-derived growth factor receptor signaling pathway (ID: 664)," "ileum-dihydrobiopterin metabolic process (ID: 148)," "jejunum-cellular response to interferon-gamma (ID: 96)," "kidney-metabolic process (ID:303)," "liver-ribosomal small subunit biogenesis (ID: 721)," "lung-cell competition in a multicellular organism (ID: 59)," "pancreas-positive regulation of respiratory burst involved in inflammatory response (ID: 519)," "pituitary gland (PituitaryG)-cellular response to nutrient (ID: 100)," "skin-regulation of mitophagy (ID: 651)," "skeletal muscle (SkMuscle)-cellular macromolecule metabolic process (ID: 84)," "skull-mRNA transcription from RNA polymerase II promoter (ID: 334)," "spleen-negative regulation of muscle adaptation (ID: 392)," "stomach-RNA phosphodiester bond hydrolysis (ID: 725)," "testis-response to TNF agonist (ID: 712)," "thymus-cellular component disassembly (ID: 74)," and "white adipose tissue (WAT)-organic substance transport (ID: 441)" ([Figure 12](#fig12){ref-type="fig"} and [Table S19](#mmc20){ref-type="supplementary-material"}).

Similarly, in these and other models, there are many more modules, each of which shows a uniquely strong correlation to a specific pathophysiological condition ([Figures 10](#fig10){ref-type="fig"}, [11](#fig11){ref-type="fig"}, [12](#fig12){ref-type="fig"}, [13](#fig13){ref-type="fig"}, [14](#fig14){ref-type="fig"}, [15](#fig15){ref-type="fig"}, and [16](#fig16){ref-type="fig"}). In such modules, each of the organs are linked to not only the top-ranked GO term but also multiple other GO terms (see [Table S17. All GO Terms in Each Module, Related to Figure 10](#mmc18){ref-type="supplementary-material"}, [Table S18. All GO Terms in Each Module, Related to Figure 11](#mmc19){ref-type="supplementary-material"}, [Table S19. All GO Terms in Each Module, Related to Figure 12](#mmc20){ref-type="supplementary-material"}, [Table S20. All GO Terms in Each Module, Related to Figure 13](#mmc21){ref-type="supplementary-material"}, [Table S21. All GO Terms in Each Module, Related to Figure 14](#mmc22){ref-type="supplementary-material"}, [Table S22. All GO Terms in Each Module, Related to Figure 15](#mmc23){ref-type="supplementary-material"}, [Table S23. All GO Terms in Each Module, Related to Figure 16](#mmc24){ref-type="supplementary-material"} for the complete list). This suggests that each of these organs forms an inter-organ cross talk network via biological functions expressed by their corresponding GO terms within the module. Hence, each of such modules may represent the signature activity of the inter-organ cross talk for the specific pathophysiological condition.

Human-Mouse Comparisons {#sec2.6}
-----------------------

Another utility of such body-wide multi-organ and multi-model datasets was also examined. The similarities and dissimilarities between experimental animal models and the human have been a subject of long-standing discussion. Herein, we provide the body-wide multi-organ and multi-model RNAseq datasets of the mouse, one of the most commonly used experimental animal models. Several multi-organ human RNAseq datasets are publicly available ([@bib16], [@bib12], [@bib54]). Hence, the comparison between our mouse datasets and such human datasets could provide an insight into the questions about the mouse-human relatedness. The gene expression pattern in each organ of each mouse model reported herein was compared with that in the corresponding organ of human subjects. The comparison was conducted by calculating Spearman\'s rank correlation coefficients between the mouse and human data ([Figures 17](#fig17){ref-type="fig"} and [18](#fig18){ref-type="fig"} and see [Transparent Methods](#mmc1){ref-type="supplementary-material"}). The human data are derived from The Human Protein Atlas (<https://www.proteinatlas.org>) and represent those of relatively healthy human subjects.Figure 17Heatmap of the Spearman\'s Correlation Coefficient between the Human and Mouse Models for Each OrganThe Spearman\'s correlation coefficients between the human and mouse models are calculated based on the FPKM of each gene.Figure 18Heatmap of the Spearman\'s Correlation Coefficient between the Human and Mouse Models for All OrgansThe Spearman\'s correlation coefficients between all human and mouse models across all organs are calculated based on the FPKM of each gene and are shown as heatmap.

The comparison between mouse and human was first made for each organ ([Figure 17](#fig17){ref-type="fig"}). The results suggest that the heart, the pancreas, the skeletal muscle (SKMuscle), and the spleen show a higher degree of similarity between the mouse and the human ([Figure 17](#fig17){ref-type="fig"}). In contrast, the testis data of the mouse and the human show the lowest similarity ([Figure 17](#fig17){ref-type="fig"}). Next, the comparison among all organs of both mouse and human was made ([Figure 18](#fig18){ref-type="fig"}). The result shows that both brain and testis exhibit far distinctive patterns among all organs in both mouse and human ([Figure 18](#fig18){ref-type="fig"}). For each of these two organs, the mouse-to-human difference is much less than the brain/testis-to-the other organs differences ([Figure 18](#fig18){ref-type="fig"}). The heart pattern appears to be closely related to that of the skeletal muscle in both mouse and human ([Figure 18](#fig18){ref-type="fig"}), suggesting that the relatedness of these two organs offset the species difference to some extent ([Figure 18](#fig18){ref-type="fig"}).

In addition, we compared the mouse heart datasets of the MI models with those derived from a patient with heart failure with ischemic heart disease ([Figure 19](#fig19){ref-type="fig"} and see [Transparent Methods](#mmc1){ref-type="supplementary-material"}). The WGCNA of the mouse heart datasets of the MI models identified 13 modules ([Figure 19](#fig19){ref-type="fig"}). A uniquely strong correlation with M.MI (the fibrosis stage) was found with "turquoise (correlation coefficient, −0.72763; p value, 5.59 × 10^−5^)," "blue (correlation coefficient, 0.719743; p value, 7.35 × 10^−5^)," and "green (correlation coefficient, 0.812496; p value, 1.42 × 10^−6^)" modules. In all of these three modules, there are several GO terms that rank among the top 20 GO terms in the human sample ([Figure 19](#fig19){ref-type="fig"}). In particular, the GO term "carbohydrate derivative biosynthetic process" shows the p values of 7.00 × 10^−4^, 5.50 × 10^−7^, and 8.60 × 10^−6^ in the human ischemic heart, "turquoise" module of the mouse M.MI heart, and "blue" module of the mouse M.MI heart, respectively ([Figure 19](#fig19){ref-type="fig"} and [Table S24](#mmc25){ref-type="supplementary-material"}). This and other signature GO terms shared by the human ischemic heart and the mouse MI heart (the full list can be explored using [Table S24](#mmc25){ref-type="supplementary-material"}) may represent common features between the human ischemic heart and the mouse MI model heart.Figure 19Comparison of the Mouse MI Model Heart with the Human Heart of a Patient with Ischemic Heart DiseaseThe modules identified by WGCNA of the mouse MI model datasets (see [Transparent Methods](#mmc1){ref-type="supplementary-material"}) are shown. The previously published ([@bib31]) publicly available human heart RNAseq datasets (GSE57344) of healthy (non-failing) subjects and of a patient with heart failure with ischemic heart disease are analyzed. The p value (Fisher\'s exact test) of each human GO term in each mouse module is shown as heatmap. See [Transparent Methods](#mmc1){ref-type="supplementary-material"} for the details. The correlation coefficient and the p value (Student\'s asymptotic t test) of each module and the complete list of GO terms with their p values (Fisher\'s exact test) are shown in [Table S24](#mmc25){ref-type="supplementary-material"}.

Discussion {#sec3}
==========

Herein we report the transcriptome landscape of the body-wide multi-organ across multi-disease and disease-related models. The mining of such comprehensive datasets provided evidence for more diverse and complex organ-to-organ and also model-to-model similarities and dissimilarities than conventionally assumed. In particular, we found the skin to be a unique organ that appears to sense and respond to disease and disease-related conditions in other non-skin organs.

The experimental validation of the inference derived from such data mining led to the uncovering of a previously less recognized cross-talk pathway between bone and skin, whereby a bone-derived systemic factor, FGF23, appears to function as a suppressor ([Figures 8](#fig8){ref-type="fig"}A--8C). In addition, we show evidence for a sensor function of the skin that is less dependent on FGF23 ([Figure 8](#fig8){ref-type="fig"}D).

Such differential gene expression in the skin could serve as biomarkers for detecting signs of diseases involving dysfunctional phosphate homeostasis, such as CKD and CKD-MBD ([@bib19], [@bib22], [@bib26], [@bib27], [@bib28], [@bib25], [@bib47]). In fact, an association of dermatological conditions with CKD has been reported ([@bib5], [@bib13]). They could also serve as biomarkers to determine whether a disease involves the FGF23 pathways. Furthermore, they could be used to determine the effects of therapeutics manipulating the FGF23 pathways ([@bib1], [@bib9]). With the recent development of a new non-invasive skin biopsy method using a micro-needle (<http://www.minderadx.com/wp-content/uploads/2015/03/MiNDERA-SID-2017-Poster-.pdf>), the utility of such skin biomarkers could be readily applicable to human subjects.

The signature activities of the inter-organ cross talk for diseases appear not to be limited to the bone-skin cross talk in phosphate homeostasis or kidney diseases. By applying WGCNA to the mouse datasets, we identified several modules consisting of multiple organ GO term (gene) units, each of which exhibits a strong correlation with a specific pathophysiological condition in each disease model ([Figures 10](#fig10){ref-type="fig"}, [11](#fig11){ref-type="fig"}, [12](#fig12){ref-type="fig"}, [13](#fig13){ref-type="fig"}, [14](#fig14){ref-type="fig"}, [15](#fig15){ref-type="fig"}, and [16](#fig16){ref-type="fig"}). Each of such modules may represent a putative inter-organ cross talk activity that signifies a specific pathophysiological condition of each disease model. Experimental validations of this finding in the future may prove such activities useful for disease diagnosis and/or selecting an effective treatment(s) for a particular disease.

The availability of such datasets also allowed us to gain insight into the relatedness between the human and animal models ([Figures 17](#fig17){ref-type="fig"}, [18](#fig18){ref-type="fig"}, and [19](#fig19){ref-type="fig"}). We found evidence for organ-to-organ variations in the degree of relatedness between the human and the mouse ([Figure 17](#fig17){ref-type="fig"}). Among the organs we studied, the testis exhibits the highest difference between the two. This finding may reflect species specificity for fertilization ([Figure 17](#fig17){ref-type="fig"}). The overall higher relatedness of certain organs, such as the heart, pancreas, skeletal muscle (SkMuscle), and spleen, than the others may reflect the evolutional conservation in the anatomical organization, cellular compositions, and/or physiological functions of these organs between the mouse and the human.

The heart appears to be highly related to the skeletal muscle, and the mouse-human difference for these two organs are relatively less ([Figure 18](#fig18){ref-type="fig"}). As both are contractile tissues, it is possible that cardiac and skeletal muscles retain highly conserved molecular and/or functional features through evolution. It is also possible that this reflects evolutionarily conserved molecular and/or functional features of peri-muscular cells, such as fibroblasts and fibroblastic cells. Alternatively, it is equally possible that the relatedness of these two organs across the different species reflect the highly conserved cell-type compositions in these two organs.

The comparison of the mouse MI models with the human ischemic heart derived from a patient with heart failure indicates several conserved features ([Figure 19](#fig19){ref-type="fig"}). Although more human subjects across various ages, sex, races, genetic backgrounds, and other accompanying conditions must be studied, the results suggest that the mouse MI models studied here reflect at least some features of human heart diseases. Further analyses of human subjects across more diverse backgrounds and their comparisons with the mouse MI models and other heart-disease-related models using the approach introduced here and other methods could facilitate better understanding of human heart diseases. Such cross-species studies could also help us select the most appropriate model to use to validate/test candidate therapeutics and also to make more appropriate interpretations of the results.

We took advantage of the comprehensive nature of the multi-organ and multi-model datasets reported herein to explore a possibility of uncovering more potential diagnostic biomarkers and candidate molecules for therapeutic treatments. Such possibilities were explored by applying a couple of other informatics tool. Likelihood analysis was conducted to make an overall multi-organ comparison rather than the conventional organ-to-organ comparison ([Figure S10](#mmc1){ref-type="supplementary-material"} and see [Transparent Methods](#mmc1){ref-type="supplementary-material"} for the details). Partial least square discriminant analysis (PLS-DA) was applied to the datasets to characterize gene-organ unit(s) that could discriminate one disease model from the others ([Figure S11](#mmc1){ref-type="supplementary-material"} and see [Transparent Methods](#mmc1){ref-type="supplementary-material"} for the details). The results appear to vary depending on which datasets are combined and analyzed. Although such analyses provided some signs of usefulness, experimental validations are required to confirm the utility of such findings. Furthermore, the reliability of such statistical analyses is critically dependent on the data size. Therefore, it is necessary to increase the sample size to the order of tens or hundreds or even more for each model. Although further work remains, the current analyses provide an initial foundation for the future studies.

Here we report the body-wide transcriptome landscape of diverse types of disease models and show its usefulness for the identification of candidate molecular signatures for disease diagnosis and treatments. We also illustrate another utility of such rich datasets by providing insights into the relationship between human and mouse models. The datasets reported herein could serve as a useful resource for the study of biology and medicine. The application of other analytical tools to these datasets and also expanding the dataset size and diversity in the future could facilitate better understanding of human biology and its applications to disease prevention and treatments.

Methods {#sec4}
=======

All methods can be found in the accompanying [Transparent Methods supplemental file](#mmc1){ref-type="supplementary-material"}.
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========================

Document S1. Transparent Methods and Figures S1--S11Table S1. Raw Data of Ejection Fraction, Related to Figure 1P value was calculated by Mann Whitney U-test.Table S2. Raw Data of Blood Glucose in STZ Model, Related to Figure 1P value was calculated by Mann Whitney U-test.Table S3. Raw Data of Inorganic Phosphorus in Plasma for CKD Models and HPi4w Model, Related to Figure 1P value was calculated by Mann Whitney U-test.Table S4. Raw Data of Creatinine in Plasma for CKD Models and HPi4w Model, Related to Figure 1P value was calculated by Mann Whitney U-test.Table S5. Raw Data of ELISA for FGF23 in Plasma for CKD Models and HPi4w Model, Related to Figure 1P value was calculated by Mann Whitney U-test.Table S6. Raw Data of qRT-PCR for GBM Model, Related to Figure 1P value was calculated by Mann Whitney U-test.Table S7. Raw Data of Step-through Test for SAMP8 Mouse, Related to Figure 1P value was calculated by Mann Whitney U-test.Table S8. Raw Data of Inorganic Phosphorus in Plasma for Phosphorus Overload Models, Related to Figure 1P value was calculated by Mann Whitney U-test.Table S9. Raw Data of ELISA for FGF23 in Plasma for Phosphorus Overload Models in WT and FGF23-Deficient Mice, Related to Figure 1P value was calculated by Mann Whitney U-test.Table S10. The Count Data of the Differential Expressed Genes Compared with WT, Related to Figures 3 and 4The numbers are shown for the one or the combination of the organs.Table S11. Raw Data, Related to Figure 3The number of all differentially expressed genes specifically in the model, but not in the corresponding sham control. The numbers are shown for the one or the combination of the organs.Table S12. Raw Data, Related to Figure 4Table S13. All GO Terms of Figures S7 and S8, Related to Figures 3 and 4Table S14. All GO Terms in Each Module, Related to Figure 5Table S15. Raw Data, Related to Figure 7. P-value was calculated by Mann Whitney U-testTable S16. Raw Data, Related to Figure 8. P-value was calculated by Mann Whitney U-testTable S17. All GO Terms in Each Module, Related to Figure 10Table S18. All GO Terms in Each Module, Related to Figure 11Table S19. All GO Terms in Each Module, Related to Figure 12Table S20. All GO Terms in Each Module, Related to Figure 13Table S21. All GO Terms in Each Module, Related to Figure 14Table S22. All GO Terms in Each Module, Related to Figure 15Table S23. All GO Terms in Each Module, Related to Figure 16Table S24. All GO terms in each module, Related to Figure 19Table S25. The Composition of the Phosphorus Diets Described in Transparent Methods, Related to Figure 1Table S26. Information about the Cancer Patients Described in Transparent Methods, Related to Figure 6Table S27. The Detailed Information of RNAseq Analysis Described in Transparent Methods, Related to Figures 3, 4 and 6Table S28. The Primer List for qRT-PCR and gRNA Information for Fgf23 Mutant Mouse Described in Transparent Methods, Related to Figures 2, 7, 8 and 9
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